Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 4 3Phase 1 3Phase 1/2 2

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Myeloid 1

Conditions

Thrombocythemia, Essential 1Polycythemia Vera 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × peginterferon alfa-2a × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

NCT05729139 2023-08-09

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Baptist Health South Florida

Phase 1 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡